Bulls vs Bears
Click to unlock major analysts' bullish and bearish positions by joining Benzinga Edge.

| Name |
|---|
Revenue Change |
Gross Change |
EBITDA Change |
EBIT Change |
Earnings Change |
Insulet was founded in 2000 with the goal of making continuous subcutaneous insulin infusion therapy for diabetes easier to use. The result was the Omnipod system, which consists of a small disposable insulin infusion device that can be operated...
Benzinga Rankings give you vital metrics on any stock – anytime.
You can purchase shares of Insulet (NASDAQ:PODD) through any online brokerage.
Other companies in Insulet’s space includes: Abbott Laboratories (NYSE:ABT), Intuitive Surgical Inc (NASDAQ:ISRG), Medtronic PLC (NYSE:MDT), Stryker Corp (NYSE:SYK) and Boston Scientific Corp (NYSE:BSX).
Insulet has a consensus price target of $239.30.
The stock price for Insulet (NASDAQ: PODD) is $134.72 last updated October 9, 2026 at 2:19 PM EDT.
There are no upcoming dividends for Insulet.
Insulet does not have any upcoming earnings scheduled.
There is no upcoming split for Insulet.
Insulet is in the Health Care sector and Health Care Equipment & Supplies industry. They are listed on the NASDAQ.